Renal Denervation Market Poised for Mainstream Adoption by 2030, New Physician Survey Reveals
FOR IMMEDIATE RELEASE
75% of practicing interventional cardiologists predict procedure will become standard hypertension treatment despite current limited adoption
[October 31st 2025] - A new market research study by medintel reveals that renal denervation (RDN) is experiencing a remarkable resurgence, with three-quarters of interventional cardiologists practicing the procedure predicting the procedure will become mainstream hypertension treatment by 2030.
The survey of 123 interventional cardiologists across the United States and Europe found that while only 37% currently perform RDN procedures, 75% of those with hands-on experience believe the technology will achieve widespread adoption within five years.
"After nearly a decade in the wilderness following early clinical setbacks, renal denervation is back with rigorous evidence and renewed industry commitment," said Kilian Toal, Partner, at medintel. "The physician confidence we're seeing represents a fundamental shift in how the medical community views this technology."
Ends.
Background Notes:
Market Revival Built on Solid Foundation
The RDN market has transformed dramatically since its early boom-and-bust cycle. Initial enthusiasm in the 2010s led to major acquisitions, including Medtronic's $800 million purchase of Ardian. However, the field went quiet after Medtronic's pivotal Symplicity HTN-3 trial failed in 2014.
The current revival is anchored by FDA approvals in November 2023 for both ReCor Medical's Paradise ultrasound system and Medtronic's Symplicity Spyral radiofrequency system—the first renal denervation devices approved in the United States. Boston Scientific's recent $540 million acquisition of SoniVie signals renewed industry investment.
Technology and Patient Selection Trends Emerge
This research survey on renal denervation practices revealed clear preferences among practicing physicians:
80% prefer radiofrequency-based systems over ultrasound technology
68% identify resistant hypertension patients (on ≥3 medications) as the ideal candidates
US and European adoption rates are remarkably similar at 36% and 39% respectively
Barriers Remain But Solutions in Sight
Despite optimism, physicians identified key obstacles to broader adoption of renal denervation:
Access and reimbursement coverage (55% of respondents)
Patient identification and responder selection (52%)
Cost and hospital economics (48%)
Lack of long-term clinical evidence (43%)
Regional differences emerged, with US physicians more concerned about long-term evidence and economics, while European colleagues focused on patient selection and awareness.
Looking Ahead
The study suggests RDN's path to mainstream status depends on addressing systemic challenges around reimbursement, patient selection tools, and long-term evidence. A pending Medicare national coverage decision could serve as a pivotal catalyst for broader US adoption.
About the Research
Methodology Note: This analysis is based on a survey of 123 (US n=67 and EU n=56) interventional cardiologists conducted in August 2025. This survey represents a focused snapshot of early adopter perspectives rather than a comprehensive market study.
medintel is a specialist medical market research consultancy. For more information, contact intel@medintel.co.uk.
medintel has the capability to conduct larger-scale quantitative and qualitative research across broader physician populations. If you're interested in more extensive RDN market research or custom studies, please get in touch.